Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study Comparing the Effectiveness and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Treatment of Acute Pain From a Migraine Headache
This study has been completed.
First Received: February 24, 2006   Last Updated: May 21, 2009   History of Changes
Sponsors and Collaborators: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
PriCara, Unit of Ortho-McNeil, Inc.
Information provided by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier: NCT00297375
  Purpose

The purpose of this study is to evaluate the effectiveness and safety of tramadol HCl/acetaminophen as a pain medication compared with placebo in the treatment of acute pain from a migraine headache. Although tramadol HCl/acetaminophen is approved to treat acute pain, it is not approved for the treatment of acute pain associated with migraine headache. The study hypothesis is that tramadol HCl/acetaminophen is safe and effective as a pain medication in the treatment of acute pain associated with a migraine headache.


Condition Intervention Phase
Migraine
Head Pain
Headache
Drug: tramadol HCl/acetaminophen
Phase IV

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study
Official Title: A Comparison of the Efficacy and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Acute Treatment of Migraine Headache Pain

Resource links provided by NLM:


Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Primary Outcome Measures:
  • Change in baseline headache pain severity at 2 hours post-dose from severe or moderate to mild or none, without using any nausea medication or other pain medication

Secondary Outcome Measures:
  • Pain free at 2, 6 and 24 hrs post-dose; difference in pain intensity and response to therapy over the first 6 hrs post-dose; reduction in occurrence and severity of symptoms; change in functional disability; subject overall rating of change.

Enrollment: 375
Study Start Date: April 2003
Study Completion Date: August 2003
Detailed Description:

Although new drugs and procedures are available to treat acute migraine pain, inadequacies in treatment still exist. The ingredients in tramadol HCl/acetaminophen tablet and the way it works may be effective in the treatment of the pain of acute migraine headache. The combination of tramadol HCl/ acetaminophen works faster than tramadol alone and lasts longer than acetaminophen alone. This is a multicenter, single-dose, outpatient, randomized (study with two groups one in treatment and one control group), double-blind (neither patient nor investigator knows which patient is receiving study drug or control treatment), placebo-controlled, parallel-group (each group receives only one type of treatment) study of adult patients who experience at least moderate pain from migraine headaches. After being randomly assigned to a group patients will leave the study center with one dose (2 tablets) of study medication, either active treatment or placebo. The next time the patient has a migraine headache of at least moderate pain, the patient will take the study medication and start to answer questions about their headache pain and pain relief in a study diary. Patients should return to the study center within 72 hours of taking this dose. The study hypothesis is that tramadol HCl/acetaminophen is safe and effective as a pain medication in the treatment of acute pain associated with a migraine headache.

2 tramadol HCl (37.5 milligrams)/acetaminophen (325 milligrams) combination tablets or 2 matching placebo (inactive substance) tablets for tramadol HCl/acetaminophen taken one time orally

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient with a history of diagnosis of migraine with or without a warning sign (aura), that meets the criteria for a migraine, for at least 1 year
  • History of migraine pain at least moderate in intensity
  • Incidence of 1 to 6 headaches per month in the past year
  • If female, using acceptable method of birth control

Exclusion Criteria:

  • Patients with routine headaches that could be confused with migraines
  • No more than 13 headache days per month in the past 6 months
  • Onset of migraines after age 50
  • Patients with migraines involving the eyes, chronic migraine or cluster headaches
  • Patients using one or more of the following medications before study entry: more than 1 type of migraine prevention medicine in the past 6 weeks, tramadol within 30 days, vitamins/herbal remedies or non-drug-related remedies for migraine for < 30 days, St. John's Wort within 30 days, investigational drug in past 30 days or any other disallowed medications
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00297375

Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
PriCara, Unit of Ortho-McNeil, Inc.
Investigators
Study Director: Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  More Information

Additional Information:
Publications:
Study ID Numbers: CR002821
Study First Received: February 24, 2006
Last Updated: May 21, 2009
ClinicalTrials.gov Identifier: NCT00297375     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
treatment
Pain
acute
migraine
headache

Study placed in the following topic categories:
Tramadol
Central Nervous System Depressants
Central Nervous System Diseases
Narcotics
Pain
Headache Disorders, Primary
Brain Diseases
Headache Disorders
Signs and Symptoms
Migraine Disorders
Analgesics, Non-Narcotic
Headache
Neurologic Manifestations
Peripheral Nervous System Agents
Analgesics
Analgesics, Opioid
Acetaminophen

Additional relevant MeSH terms:
Tramadol
Physiological Effects of Drugs
Nervous System Diseases
Central Nervous System Depressants
Central Nervous System Diseases
Narcotics
Pain
Headache Disorders, Primary
Brain Diseases
Pharmacologic Actions
Headache Disorders
Signs and Symptoms
Sensory System Agents
Migraine Disorders
Analgesics, Non-Narcotic
Therapeutic Uses
Headache
Neurologic Manifestations
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Analgesics, Opioid
Acetaminophen

ClinicalTrials.gov processed this record on July 02, 2009